US regulators have approved Bayer/Janssen’s Xarelto to cut the risk of major cardiovascular (CV) events in people with chronic coronary or peripheral artery disease (CAD/PAD).
Read More
Bayer/Janssen’s bloodthinner Xarelto has shown clear efficacy in preventing major cardiovascular events (MACE) in patients with coronary or peripheral artery disease taking part in the COMPASS trial, prompting an early halt to the late-stage study.
Read More
AstraZeneca’s Brilinta has been hit with another setback after failing to show superiority over veteran bloodthinner clopidogrel in patients with peripheral arterial disease (PAD).
Read More
